BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28046094)

  • 1. Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation.
    Goh LL; Lim CW; Sim WC; Toh LX; Leong KP
    PLoS One; 2017; 12(1):e0169233. PubMed ID: 28046094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review.
    Dorji PW; Tshering G; Na-Bangchang K
    J Clin Pharm Ther; 2019 Aug; 44(4):508-524. PubMed ID: 30980418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a multi-gene qPCR-based pharmacogenomics panel across major ethnic groups in Singapore and Indonesia.
    Kothary AS; Mahendra C; Tan M; Min Tan EJ; Hong Yi JP; Gabriella ; Hui Jocelyn TX; Haruman JS; Tan Z; Lee CK; Lezhava A; Yan B; Irwanto A
    Pharmacogenomics; 2021 Nov; 22(16):1041-1056. PubMed ID: 34693729
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population.
    Verma SS; Keat K; Li B; Hoffecker G; Risman M; ; Sangkuhl K; Whirl-Carrillo M; Dudek S; Verma A; Klein TE; Ritchie MD; Tuteja S
    J Transl Med; 2022 Nov; 20(1):550. PubMed ID: 36443877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population.
    Shi Y; Xiang P; Li L; Shen M
    Forensic Sci Int; 2011 Apr; 207(1-3):183-7. PubMed ID: 21071160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
    Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
    Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.
    Liou YH; Lin CT; Wu YJ; Wu LS
    J Hum Genet; 2006; 51(10):857. PubMed ID: 16924387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.
    Lim JS; Chen XA; Singh O; Yap YS; Ng RC; Wong NS; Wong M; Lee EJ; Chowbay B
    Br J Clin Pharmacol; 2011 May; 71(5):737-50. PubMed ID: 21480951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational pharmacogenotype extraction from clinical next-generation sequencing.
    Shugg T; Ly RC; Osei W; Rowe EJ; Granfield CA; Lynnes TC; Medeiros EB; Hodge JC; Breman AM; Schneider BP; Sahinalp SC; Numanagić I; Salisbury BA; Bray SM; Ratcliff R; Skaar TC
    Front Oncol; 2023; 13():1199741. PubMed ID: 37469403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.
    Dong Y; Xiao H; Wang Q; Zhang C; Liu X; Yao N; Sheng H; Li H
    Int J Clin Exp Med; 2015; 8(10):18917-26. PubMed ID: 26770516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodology for clinical genotyping of CYP2D6 and CYP2C19.
    Carvalho Henriques B; Buchner A; Hu X; Wang Y; Yavorskyy V; Wallace K; Dong R; Martens K; Carr MS; Behroozi Asl B; Hague J; Sivapalan S; Maier W; Dernovsek MZ; Henigsberg N; Hauser J; Souery D; Cattaneo A; Mors O; Rietschel M; Pfeffer G; Hume S; Aitchison KJ
    Transl Psychiatry; 2021 Nov; 11(1):596. PubMed ID: 34811360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population.
    Ganoci L; Božina T; Mirošević Skvrce N; Lovrić M; Mas P; Božina N
    Drug Metab Pers Ther; 2017 Mar; 32(1):11-21. PubMed ID: 28272018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
    van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
    Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
    Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
    J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.